HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Acquisition Fund Expected To Reach $40 Mil. With Offering

This article was originally published in The Rose Sheet

Executive Summary

Chattem is hoping to net approximately $60 mil. from a new share offering that will be used to retire bank debt and fund future acquisitions. Announced June 17, the offering of 1.8 mil. shares is expected to be complete in early July, Chattem said

You may also be interested in...



After Williams Buy, Combe Won’t Be Stuck In Men’s Hair Care

Combe Incorporated's planned acquisition of Glen Rock, N.J.-based J.B. Williams is the company's most aggressive expansion move to date and will provide the business with a stronger foothold in personal care

After Williams Buy, Combe Won’t Be Stuck In Men’s Hair Care

Combe Incorporated's planned acquisition of Glen Rock, N.J.-based J.B. Williams is the company's most aggressive expansion move to date and will provide the business with a stronger foothold in personal care

Chattem offering

Consumer products marketer is postponing public offering of 1.8 mil. shares due to unfavorable market conditions, Chattem says June 28. Chattem initially announced plans for the offering June 17 and had expected to complete it by early July. Offering was estimated to net $60 mil., which would be used to retire bank debt and fund future acquisitions (1"The Rose Sheet" June 24, 2002, p. 12)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel